Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,157.49
+14.371.26%
Pre-market: 1,163.806.31+0.55%07:15 EDT
Volume:2.13M
Turnover:2.47B
Market Cap:1.09T
PE:38.86
High:1,177.07
Open:1,147.15
Low:1,139.98
Close:1,143.12
52wk High:1,292.65
52wk Low:783.85
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.95
T/O Rate:0.23%
Dividend:6.69
Dividend Rate:0.58%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:32.30
PE(LYR):50.44

Loading ...

Earnings Look Great. Only 7 Stocks Agree

Bellwether Stocks Movement
·
2 hours ago

AI Will Revolutionize Medicine. This Company Provides the Plumbing

Analyst Calls
·
3 hours ago

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
3 hours ago

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
4 hours ago

Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

TIPRANKS
·
18 hours ago

General Medicine Raises $120 Mln to Build the Healthcare Store

Reuters
·
Yesterday

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Yesterday

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Yesterday

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Yesterday

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

Eli Lilly treatment of pancreatic cancer granted orphan designation

TIPRANKS
·
Oct 05

TRex Bio Files for Nasdaq IPO

MT Newswires Live
·
Oct 05

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
Oct 05

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

One Weekend, Thousands Of Compounds: Inside Microsoft's New AI Biology Model

AI Industry Frontlines
·
Oct 03

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03